Erratum to “Subject and clinician experience with the levonorgestrel-releasing intrauterine system”
TL;DR: Over 95% of women had successful insertions of the LNG IUS at first attempt, and less than 1% were unsuccessful after two attempts, and one-year continuation rates were comparable to those of other reversible methods.
About: This article is published in Contraception.The article was published on 2008-06-01. It has received 19 citations till now. The article focuses on the topics: Obstetrics and gynaecology.
Citations
More filters
TL;DR: After censoring for cesarean delivery and adjusting for parity, misoprostol–cervical Foley resulted in twice the chance of delivering before either single-agent method.
110 citations
TL;DR: Rates of discontinuation of long-acting reversible contraception at 6 months is low and not increased in adolescents and young women, and intrauterine devices and the implant should be considered as first-line contraceptive options among all women to reduce unintended pregnancy.
108 citations
Additional excerpts
...Private 2,564 (44) 2,383 (44) 181 (42) Public 1,024 (17) 935 (17) 89 (21)...
[...]
TL;DR: The association between HT use and the risk for breast cancer shows a large variation between various forms of HT, and also the use of LNG‐IUS may carry a risk.
Abstract: The purpose of this study was to evaluate the association between postmenopausal hormone therapy (HT) and the risk for breast cancer in recently postmenopausal Finnish women. All Finnish women with first invasive breast cancer diagnosed between the ages of 50 and 62 years during 1995-2007 (n = 9,956) were identified from the Finnish Cancer Registry. For each case, 3 controls of the same age were retrieved from the Finnish Population Register. The cases and controls were linked to the national medical reimbursement register to assess the use of HT. The odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer were calculated with conditional logistic regression analysis, adjusting for parity, age at the first birth and health care district. Estradiol-only therapy (991 users with breast cancer, n) or oral progestagen (n = 138) was not accompanied by an increased risk. Estradiol-progestagen therapy (EPT) (n = 1,731) was associated with an elevated risk in the whole series (OR 1.36; 95% CI 1.27-1.46). The risk became detectable in less than 3 years of use. Continuous EPT use tended to be associated with a higher risk for breast cancer than the sequential EPT use. The use of tibolone (n = 80) (1.36; 1.15-1.96), a levonorgestrel-releasing intrauterine system (LNG-IUS) alone (n = 154) (1.45; 1.97-1.77) or as a complement to estradiol (n = 137) (2.15; 1.72-2.68) was also associated with an increased risk. The association between HT use and the risk for breast cancer shows a large variation between various forms of HT, and also the use of LNG-IUS may carry a risk.
96 citations
TL;DR: In this paper, a 52-mg Levonorgestrel intrauterine contraceptive (LNG20) was evaluated for up to 7 years of use in women aged 16-35 years.
75 citations
TL;DR: The LNG-IUS is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily, and is highly effective, with a typical-use first year pregnancy rate of 0.1% – similar to surgical tubal occlusion.
Abstract: Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing intrauterine system (LNG-IUS) is a T-shaped IUD with a steroid reservoir containing 52 mg of levonorgestrel that is released at an initial rate of 20 μg daily. It is highly effective, with a typical-use first year pregnancy rate of 0.1% – similar to surgical tubal occlusion. It is approved for 5 years of contraceptive use, and there is evidence that it can be effective for up to 7 years of continuous use. After removal, there is rapid return to fertility, with 1-year life-table pregnancy rates of 89 per 100 for women less than 30 years of age. Most users experience a dramatic reduction in menstrual bleeding, and about 15% to 20% of women become amenorrheic 1 year after insertion. The device’s strong local effects on the endometrium benefit women with various benign gynecological conditions such as menorrhagia, dysmenorrhea, leiomyomata, adenomyosis, and endometriosis. There is also evidence to support its role in endometrial protection during postmenopausal estrogen replacement therapy, and in the treatment of endometrial hyperplasia.
68 citations
References
More filters
TL;DR: The LNG-IUD is a long-acting reversible contraceptive method for 5 years with a pregnancy rate comparable to female sterilization and the incidence of PID is low even in young women, and the positive health effects such as decreased menstrual blood loss and increased blood haemoglobin concentration make it a favorable combination of hormonal and intrauterine contraception.
464 citations
TL;DR: A levonorgestrel-releasing IUD and the Copper T 380Ag IUD were in randomized comparison for seven years in five clinics, representing the most effective reversible contraceptive methods yet studied in long-term randomized trials.
227 citations
TL;DR: For the first time, a protective effect of the levonorgestrel IUD against pelvic inflammatory disease as compared with the Nova-T was seen statistically, and may help to solve one of the major concerns associated with intrauterine contraception.
187 citations
TL;DR: These two intrauterine devices are the most effective long-term, reversible IUDs yet reported in the literature and no other contraceptive methods have exhibited such low long- term pregnancy rates in randomized comparative trials.
180 citations
TL;DR: Information received at the insertion visit is strongly associated with increased user satisfaction among the users of the levonorgestrel intrauterine system and the association between high user satisfaction and advance information was strongest regarding the possibility of missing periods.
130 citations